A pilot study to evaluate the safety and efficacy of interferon beta-1a (IFN ß-1a) in the treatment of patients presenting with Ebola virus illness

Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)0 sites50 target enrollmentJuly 19, 2016

ConditionsAcute ebola virus disease Infections and Infestations

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Acute ebola virus disease
Sponsor: Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)
Enrollment: 50
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

2017 results in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321269/ (added 01/03/2019)

Registry

who.int

Start Date

July 19, 2016

End Date

April 19, 2016

Last Updated

7 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Sustainable health Foundation (FOSAD) & Center of Excellence for Training on Research and Priority Diseases (CEFORPAG)

Eligibility Criteria

Inclusion Criteria

•1\. Able to provide informed consent (ubstitute decision maker may provide informed consent in cases where the patient is ill and unable to provide informed consent)
•2\. Aged between 18 and 70 years on the day of inclusion
•3\. In the treatment centre
•4\. Confirmed ebola virus infection by RT\-PCR
•5\. Symptom onset \< 6 days
•6\. Able to comply with trial procedures

Exclusion Criteria

•1\. Known hypersensitivity to IFN ß preparations
•2\. Pregnancy
•3\. Chronic liver disease with synthetic dysfunction and/or decompensation, history of bleeding
•4\. Moderate to severe congestive heart failure \- grade III or IV left ventricular function
•5\. Previous history of serious psychiatric illness
•6\. History of sever or active autoimmune disease